{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:59:35Z","timestamp":1794574775512,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["P01NS074969"],"award-info":[{"award-number":["P01NS074969"]}]},{"name":"NIH","award":["P01NS074969"],"award-info":[{"award-number":["P01NS074969"]}]},{"name":"NIH","award":["U19AG069701"],"award-info":[{"award-number":["U19AG069701"]}]},{"name":"NIH","award":["U19AG069701"],"award-info":[{"award-number":["U19AG069701"]}]},{"name":"Mayo Alzheimer\u2019s Disease Research Center Developmental Grant"},{"name":"Lewy Body Dementia Center Without Walls","award":["U54NS110435"],"award-info":[{"award-number":["U54NS110435"]}]},{"name":"Lewy Body Dementia Center Without Walls","award":["U54NS110435"],"award-info":[{"award-number":["U54NS110435"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The aggregation and spread of \u03b1-synuclein (\u03b1-Syn) protein and related neuronal toxicity are the key pathological features of Parkinson\u2019s disease (PD) and Lewy body dementia (LBD). Studies have shown that pathological species of \u03b1-Syn and tau can spread in a prion-like manner between neurons, although these two proteins have distinct pathological roles and contribute to different neurodegenerative diseases. It is reported that the low-density lipoprotein receptor-related protein 1 (LRP1) regulates the spread of tau proteins; however, the molecular regulatory mechanisms of \u03b1-Syn uptake and spread, and whether it is also regulated by LRP1, remain poorly understood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We established <jats:italic>LRP1<\/jats:italic> knockout (<jats:italic>LRP1<\/jats:italic>-KO) human induced pluripotent stem cells (iPSCs) isogenic lines using a CRISPR\/Cas9 strategy and generated iPSC-derived neurons (iPSNs) to test the role of LRP1 in \u03b1-Syn uptake. We treated the iPSNs with fluorescently labeled \u03b1-Syn protein and measured the internalization of \u03b1-Syn using flow cytometry. Three forms of \u03b1-Syn species were tested: monomers, oligomers, and pre-formed fibrils (PFFs). To examine whether the lysine residues of \u03b1-Syn are involved in LRP1-mediated uptake, we capped the amines of lysines on \u03b1-Syn with sulfo-NHS acetate and then measured the internalization. We also tested whether the N-terminus of \u03b1-Syn is critical for LRP1-mediated internalization. Lastly, we investigated the role of Lrp1 in regulating \u03b1-Syn spread with a neuronal <jats:italic>Lrp1<\/jats:italic> conditional knockout (<jats:italic>Lrp1<\/jats:italic>-nKO) mouse model. We generated adeno-associated viruses (AAVs) that allowed for distinguishing the \u03b1-Syn expression versus spread and injected them into the hippocampus of six-month-old <jats:italic>Lrp1<\/jats:italic>-nKO mice and the littermate wild type (WT) controls. The spread of \u03b1-Syn was evaluated three months after the injection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that the uptake of both monomeric and oligomeric \u03b1-Syn was significantly reduced in iPSNs with <jats:italic>LRP1<\/jats:italic>-KO compared with the WT controls. The uptake of \u03b1-Syn PFFs was also inhibited in <jats:italic>LRP1<\/jats:italic>-KO iPSNs, albeit to a much lesser extent compared to \u03b1-Syn monomers and oligomers. The blocking of lysine residues on \u03b1-Syn effectively decreased the uptake of \u03b1-Syn in iPSNs and the N-terminus of \u03b1-Syn was critical for LRP1-mediated \u03b1-Syn uptake. Finally, in the <jats:italic>Lrp1<\/jats:italic>-nKO mice, the spread of \u03b1-Syn was significantly reduced compared with the WT littermates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We identified LRP1 as a key regulator of \u03b1-Syn neuronal uptake, as well as an important mediator of \u03b1-Syn spread in the brain. This study provides new knowledge on the physiological and pathological role of LRP1 in \u03b1-Syn trafficking and pathology, offering insight for the treatment of synucleinopathies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13024-022-00560-w","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T05:02:55Z","timestamp":1662094975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":127,"title":["LRP1 is a neuronal receptor for \u03b1-synuclein uptake and spread"],"prefix":"10.1186","volume":"17","author":[{"given":"Kai","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka A.","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Meneses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Caroline","family":"Raulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjung","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Kanekiyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"Golde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojun","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8648-9422","authenticated-orcid":false,"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci. 2013;14:38\u201348.","journal-title":"Nat Rev Neurosci"},{"key":"560_CR2","doi-asserted-by":"crossref","unstructured":"Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinson\u2019s disease - lessons and emerging principles. Mol Neurodegener. 2019;14:29.","DOI":"10.1186\/s13024-019-0329-1"},{"key":"560_CR3","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burre","year":"2010","unstructured":"Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science (New York, NY). 2010;329:1663\u20137.","journal-title":"Science (New York, NY)"},{"key":"560_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","volume":"65","author":"VM Nemani","year":"2010","unstructured":"Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of \u03b1-Synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66\u201379.","journal-title":"Neuron"},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.0535-12.2012","volume":"32","author":"D Scott","year":"2012","unstructured":"Scott D, Roy S. \u03b1-Synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci. 2012;32:10129\u201335.","journal-title":"J Neurosci"},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"11113","DOI":"10.1073\/pnas.1903049116","volume":"116","author":"J Sun","year":"2019","unstructured":"Sun J, Wang L, Bao H, Premi S, Das U, Chapman Edwin R, Roy S. Functional cooperation of \u03b1-synuclein and VAMP2 in synaptic vesicle recycling. Proc Natl Acad Sci. 2019;116:11113\u20135.","journal-title":"Proc Natl Acad Sci"},{"key":"560_CR7","doi-asserted-by":"crossref","unstructured":"Schechter M, Grigoletto J, Abd-Elhadi S, Glickstein H, Friedman A, Serrano GE, Beach TG, Sharon R. A role for alpha-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson\u2019s disease. Mol Neurodegener. 2020;15:24.","DOI":"10.1186\/s13024-020-00370-y"},{"key":"560_CR8","doi-asserted-by":"crossref","unstructured":"El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, Gibson MJ, Curran MD, Court JA, Mann DM, Ikeda S, et al. Alpha-synuclein implicated in Parkinson\u2019s disease is present in extracellular biological fluids, including human plasma. FASEB J. 2003;17:1945\u20137.","DOI":"10.1096\/fj.03-0098fje"},{"key":"560_CR9","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","volume":"25","author":"HJ Lee","year":"2005","unstructured":"Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci. 2005;25:6016\u201324.","journal-title":"J Neurosci"},{"key":"560_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022225","volume":"6","author":"E Emmanouilidou","year":"2011","unstructured":"Emmanouilidou E, Elenis D, Papasilekas T, Stranjalis G, Gerozissis K, Ioannou PC, Vekrellis K. Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS ONE. 2011;6: e22225.","journal-title":"PLoS ONE"},{"key":"560_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","volume":"15","author":"BA Hijaz","year":"2020","unstructured":"Hijaz BA, Volpicelli-Daley LA. Initiation and propagation of alpha-synuclein aggregation in the nervous system. Mol Neurodegener. 2020;15:19.","journal-title":"Mol Neurodegener"},{"key":"560_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrm2873","volume":"11","author":"P Brundin","year":"2010","unstructured":"Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2010;11:301\u20137.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"560_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/S1474-4422(10)70213-1","volume":"9","author":"E Angot","year":"2010","unstructured":"Angot E, Steiner JA, Hansen C, Li JY, Brundin P. Are synucleinopathies prion-like disorders? The Lancet Neurology. 2010;9:1128\u201338.","journal-title":"The Lancet Neurology"},{"key":"560_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier DJ, Obeso JA, Halliday GM. Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017;18:101\u201313.","journal-title":"Nat Rev Neurosci"},{"key":"560_CR15","doi-asserted-by":"publisher","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","volume":"27","author":"KM Danzer","year":"2007","unstructured":"Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27:9220\u201332.","journal-title":"J Neurosci"},{"key":"560_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","volume":"111","author":"KM Danzer","year":"2009","unstructured":"Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem. 2009;111:192\u2013203.","journal-title":"J Neurochem"},{"key":"560_CR17","doi-asserted-by":"crossref","unstructured":"Luk KC, Song C, O\u2019Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106:20051\u20136.","DOI":"10.1073\/pnas.0908005106"},{"key":"560_CR18","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI43366","volume":"121","author":"C Hansen","year":"2011","unstructured":"Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011;121:715\u201325.","journal-title":"J Clin Invest"},{"key":"560_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","volume":"16","author":"S Koga","year":"2021","unstructured":"Koga S, Sekiya H, Kondru N, Ross OA, Dickson DW. Neuropathology and molecular diagnosis of Synucleinopathies. Mol Neurodegener. 2021;16:83.","journal-title":"Mol Neurodegener"},{"key":"560_CR20","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev.biochem.71.110601.135342","volume":"71","author":"J Herz","year":"2002","unstructured":"Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem. 2002;71:405\u201334.","journal-title":"Annu Rev Biochem"},{"key":"560_CR21","doi-asserted-by":"crossref","unstructured":"Kanekiyo T, Bu G. The low-density lipoprotein receptor-related protein 1 and amyloid-\u03b2 clearance in Alzheimer\u2019s disease. Frontiers in aging neuroscience. 2014;6:93.","DOI":"10.3389\/fnagi.2014.00093"},{"key":"560_CR22","doi-asserted-by":"publisher","first-page":"19276","DOI":"10.1523\/JNEUROSCI.3487-13.2013","volume":"33","author":"T Kanekiyo","year":"2013","unstructured":"Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G. Neuronal clearance of amyloid-\u03b2 by endocytic receptor LRP1. J Neurosci. 2013;33:19276\u201383.","journal-title":"J Neurosci"},{"key":"560_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501\u201318.","journal-title":"Nat Rev Neurol"},{"key":"560_CR24","doi-asserted-by":"crossref","unstructured":"Zhao N, Liu CC, Qiao W, Bu G. Apolipoprotein E, receptors, and modulation of Alzheimer\u2019s disease. Biol Psychiatry. 2018;83:347\u201357.","DOI":"10.1016\/j.biopsych.2017.03.003"},{"key":"560_CR25","doi-asserted-by":"crossref","unstructured":"Bu G. Apolipoprotein E and its receptors in Alzheimer\u2019s disease: pathways, pathogenesis and therapy. Nat Rev Neurosci. 2009;10:333\u201344.","DOI":"10.1038\/nrn2620"},{"key":"560_CR26","doi-asserted-by":"crossref","unstructured":"Kanekiyo T, Bu G. The low-density lipoprotein receptor-related protein 1 and amyloid-beta clearance in Alzheimer\u2019s disease. Front Aging Neurosci. 2014;6:93.","DOI":"10.3389\/fnagi.2014.00093"},{"key":"560_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13024-020-00366-8","volume":"15","author":"J Robert","year":"2020","unstructured":"Robert J, Button EB, Martin EM, McAlary L, Gidden Z, Gilmour M, Boyce G, Caffrey TM, Agbay A, Clark A, et al. Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E. Mol Neurodegener. 2020;15:23.","journal-title":"Mol Neurodegener"},{"key":"560_CR28","doi-asserted-by":"crossref","unstructured":"Shinohara M, Tachibana M, Kanekiyo T, Bu G: Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. J Lipid Res. 2017;58:1267\u201381.","DOI":"10.1194\/jlr.R075796"},{"key":"560_CR29","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41586-020-2156-5","volume":"580","author":"JN Rauch","year":"2020","unstructured":"Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, Leshuk C, Hernandez I, Wegmann S, Hyman BT, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381\u20135.","journal-title":"Nature"},{"key":"560_CR30","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.molmed.2020.03.012","volume":"26","author":"N Uemura","year":"2020","unstructured":"Uemura N, Uemura MT, Luk KC, Lee VM, Trojanowski JQ. Cell-to-Cell Transmission of Tau and alpha-Synuclein. Trends Mol Med. 2020;26:936\u201352.","journal-title":"Trends Mol Med"},{"key":"560_CR31","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1093\/hmg\/ddx155","volume":"26","author":"J Zhao","year":"2017","unstructured":"Zhao J, Davis MD, Martens YA, Shinohara M, Graff-Radford NR, Younkin SG, Wszolek ZK, Kanekiyo T, Bu G. APOE \u03b54\/\u03b54 diminishes neurotrophic function of human iPSC-derived astrocytes. Hum Mol Genet. 2017;26:2690\u2013700.","journal-title":"Hum Mol Genet"},{"key":"560_CR32","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00401-022-02421-8","volume":"143","author":"Y Jin","year":"2022","unstructured":"Jin Y, Li F, Sonoustoun B, Kondru NC, Martens YA, Qiao W, Heckman MG, Ikezu TC, Li Z, Burgess JD, et al. APOE4 exacerbates \u03b1-synuclein seeding activity and contributes to neurotoxicity in Alzheimer\u2019s disease with Lewy body pathology. Acta Neuropathologica. 2022;143:641.","journal-title":"Acta Neuropathologica"},{"key":"560_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-020-00361-z","volume":"15","author":"MS Goodwin","year":"2020","unstructured":"Goodwin MS, Croft CL, Futch HS, Ryu D, Ceballos-Diaz C, Liu X, Paterno G, Mejia C, Deng D, Menezes K, et al. Utilizing minimally purified secreted rAAV for rapid and cost-effective manipulation of gene expression in the CNS. Mol Neurodegener. 2020;15:15.","journal-title":"Mol Neurodegener"},{"key":"560_CR34","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1172\/JCI124853","volume":"129","author":"M Tachibana","year":"2019","unstructured":"Tachibana M, Holm ML, Liu CC, Shinohara M, Aikawa T, Oue H, Yamazaki Y, Martens YA, Murray ME, Sullivan PM, et al. APOE4-mediated amyloid-beta pathology depends on its neuronal receptor LRP1. J Clin Invest. 2019;129:1272\u20137.","journal-title":"J Clin Invest"},{"key":"560_CR35","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0074-7696(01)09011-8","volume":"209","author":"G Bu","year":"2001","unstructured":"Bu G. The roles of receptor-associated protein (RAP) as a molecular chaperone for members of the LDL receptor family. Int Rev Cytol. 2001;209:79\u2013116.","journal-title":"Int Rev Cytol"},{"key":"560_CR36","doi-asserted-by":"publisher","first-page":"31305","DOI":"10.1074\/jbc.274.44.31305","volume":"274","author":"JG Neels","year":"1999","unstructured":"Neels JG, van Den Berg BM, Lookene A, Olivecrona G, Pannekoek H, van Zonneveld AJ. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem. 1999;274:31305\u201311.","journal-title":"J Biol Chem"},{"key":"560_CR37","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1152\/physrev.00033.2007","volume":"88","author":"AP Lillis","year":"2008","unstructured":"Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev. 2008;88:887\u2013918.","journal-title":"Physiol Rev"},{"key":"560_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1172\/JCI1240","volume":"101","author":"A Rohlmann","year":"1998","unstructured":"Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest. 1998;101:689\u201395.","journal-title":"J Clin Invest"},{"key":"560_CR39","doi-asserted-by":"publisher","first-page":"17068","DOI":"10.1523\/JNEUROSCI.4067-10.2010","volume":"30","author":"Q Liu","year":"2010","unstructured":"Liu Q, Trotter J, Zhang J, Peters MM, Cheng H, Bao J, Han X, Weeber EJ, Bu G. Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci. 2010;30:17068\u201378.","journal-title":"J Neurosci"},{"key":"560_CR40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-021-00476-x","volume":"16","author":"DC Chung","year":"2021","unstructured":"Chung DC, Roemer S, Petrucelli L, Dickson DW. Cellular and pathological heterogeneity of primary tauopathies. Mol Neurodegener. 2021;16:57.","journal-title":"Mol Neurodegener"},{"key":"560_CR41","doi-asserted-by":"publisher","first-page":"aah3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X Mao","year":"2016","unstructured":"Mao X, Ou MT, Karuppagounder SS, Kam TI, Yin X, Xiong Y, Ge P, Umanah GE, Brahmachari S, Shin JH, et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016;353:aah3374.","journal-title":"Science"},{"key":"560_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100715","volume":"296","author":"JM Cooper","year":"2021","unstructured":"Cooper JM, Lathuiliere A, Migliorini M, Arai AL, Wani MM, Dujardin S, Muratoglu SC, Hyman BT, Strickland DK. Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. J Biol Chem. 2021;296: 100715.","journal-title":"J Biol Chem"},{"key":"560_CR43","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1523\/JNEUROSCI.5699-09.2010","volume":"30","author":"E Emmanouilidou","year":"2010","unstructured":"Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, Margaritis LH, Stefanis L, Vekrellis K. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30:6838\u201351.","journal-title":"J Neurosci"},{"key":"560_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-016-0143-y","volume":"12","author":"Y Wang","year":"2017","unstructured":"Wang Y, Balaji V, Kaniyappan S, Kruger L, Irsen S, Tepper K, Chandupatla R, Maetzler W, Schneider A, Mandelkow E, Mandelkow EM. The release and trans-synaptic transmission of Tau via exosomes. Mol Neurodegener. 2017;12:5.","journal-title":"Mol Neurodegener"},{"key":"560_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13024-020-00396-2","volume":"15","author":"Z Ruan","year":"2020","unstructured":"Ruan Z, Delpech JC, Venkatesan Kalavai S, Van Enoo AA, Hu J, Ikezu S, Ikezu T. P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice. Mol Neurodegener. 2020;15:47.","journal-title":"Mol Neurodegener"},{"key":"560_CR46","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.15252\/embj.201593411","volume":"35","author":"S Abounit","year":"2016","unstructured":"Abounit S, Bousset L, Loria F, Zhu S, de Chaumont F, Pieri L, Olivo-Marin JC, Melki R, Zurzolo C. Tunneling nanotubes spread fibrillar alpha-synuclein by intercellular trafficking of lysosomes. EMBO J. 2016;35:2120\u201338.","journal-title":"EMBO J"},{"key":"560_CR47","doi-asserted-by":"crossref","unstructured":"Dieriks BV, Park TI, Fourie C, Faull RL, Dragunow M, Curtis MA. \u03b1-synuclein transfer through tunneling nanotubes occurs in SH-SY5Y cells and primary brain pericytes from Parkinson\u2019s disease patients. Sci Rep. 2017;7:42984.","DOI":"10.1038\/srep42984"},{"key":"560_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40478-016-0386-4","volume":"4","author":"M Tardivel","year":"2016","unstructured":"Tardivel M, Begard S, Bousset L, Dujardin S, Coens A, Melki R, Buee L, Colin M. Tunneling nanotube (TNT)-mediated neuron-to neuron transfer of pathological Tau protein assemblies. Acta Neuropathol Commun. 2016;4:117.","journal-title":"Acta Neuropathol Commun"},{"key":"560_CR49","doi-asserted-by":"publisher","first-page":"8637","DOI":"10.1073\/pnas.0712179105","volume":"105","author":"M Vilar","year":"2008","unstructured":"Vilar M, Chou HT, Luhrs T, Maji SK, Riek-Loher D, Verel R, Manning G, Stahlberg H, Riek R. The fold of alpha-synuclein fibrils. Proc Natl Acad Sci U S A. 2008;105:8637\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"560_CR50","doi-asserted-by":"crossref","unstructured":"Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson\u2019s disease. Biochemistry. 2003;42:7871\u20138.","DOI":"10.1021\/bi030086j"},{"key":"560_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1126\/science.1079469","volume":"300","author":"R Kayed","year":"2003","unstructured":"Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486\u20139.","journal-title":"Science"},{"key":"560_CR52","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(17)30400-3","volume":"17","author":"R Guerreiro","year":"2018","unstructured":"Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, Shepherd CE, Parkkinen L, Darwent L, Heckman MG, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 2018;17:64\u201374.","journal-title":"Lancet Neurol"},{"key":"560_CR53","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor JP, Thomas A, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:5.","journal-title":"Mol Neurodegener"},{"key":"560_CR54","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.23659","volume":"72","author":"DJ Irwin","year":"2012","unstructured":"Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72:587\u201398.","journal-title":"Ann Neurol"},{"key":"560_CR55","doi-asserted-by":"crossref","unstructured":"Papapetropoulos S, Farrer MJ, Stone JT, Milkovic NM, Ross OA, Calvo L, McQuorquodale D, Mash DC. Phenotypic associations of tau and ApoE in Parkinson\u2019s disease. Neurosci Lett. 2007;414:141\u20134.","DOI":"10.1016\/j.neulet.2006.12.008"},{"key":"560_CR56","doi-asserted-by":"crossref","unstructured":"Pu JL, Jin CY, Wang ZX, Fang Y, Li YL, Xue NJ, Zheng R, Lin ZH, Yan YQ, Si XL, et al. Apolipoprotein E genotype contributes to motor progression in Parkinson\u2019s disease. Mov Disord. 2021;37:196.","DOI":"10.1002\/mds.28805"},{"key":"560_CR57","doi-asserted-by":"crossref","unstructured":"Kim R, Park S, Yoo D, Jun JS, Jeon B. Impact of the apolipoprotein E epsilon4 allele on early Parkinson\u2019s disease progression. Parkinsonism Relat Disord. 2021;83:66\u201370.","DOI":"10.1016\/j.parkreldis.2021.01.004"},{"key":"560_CR58","doi-asserted-by":"publisher","first-page":"eaay3069","DOI":"10.1126\/scitranslmed.aay3069","volume":"12","author":"AA Davis","year":"2020","unstructured":"Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A, Haines JN, Dhavale DD, Miller R, Choudhury FA, et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med. 2020;12:eaay3069.","journal-title":"Sci Transl Med"},{"key":"560_CR59","doi-asserted-by":"crossref","unstructured":"Tan MMX, Lawton MA, Jabbari E, Reynolds RH, Iwaki H, Blauwendraat C, Kanavou S, Pollard MI, Hubbard L, Malek N, et al. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson\u2019s Disease. Mov Disord. 2021;36:424\u201333.","DOI":"10.1002\/mds.28342"},{"key":"560_CR60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/archneur.63.2.189","volume":"63","author":"X Huang","year":"2006","unstructured":"Huang X, Chen P, Kaufer DI, Troster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. Arch Neurol. 2006;63:189\u201393.","journal-title":"Arch Neurol"},{"key":"560_CR61","doi-asserted-by":"crossref","unstructured":"Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, Dong X, Maple-Grodem J, Campbell MC, Elbaz A, et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson\u2019s disease. Nat Genet. 2021;53:787\u201393.","DOI":"10.1038\/s41588-021-00847-6"},{"key":"560_CR62","doi-asserted-by":"crossref","unstructured":"Jin Y, Li F, Sonoustoun B, Kondru NC, Martens YA, Qiao W, Heckman MG, Ikezu TC, Li Z, Burgess JD, et al. APOE4 exacerbates alpha-synuclein seeding activity and contributes to neurotoxicity in Alzheimer\u2019s disease with Lewy body pathology. Acta Neuropathol. 2022;143:641.","DOI":"10.1007\/s00401-022-02421-8"},{"key":"560_CR63","doi-asserted-by":"publisher","first-page":"e1182","DOI":"10.1212\/WNL.0000000000006212","volume":"91","author":"DW Dickson","year":"2018","unstructured":"Dickson DW, Heckman MG, Murray ME, Soto AI, Walton RL, Diehl NN, van Gerpen JA, Uitti RJ, Wszolek ZK, Ertekin-Taner N, et al. APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91:e1182\u201395.","journal-title":"Neurology"},{"key":"560_CR64","first-page":"E3138","volume":"110","author":"BB Holmes","year":"2013","unstructured":"Holmes BB, DeVos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci USA. 2013;110:E3138-3147.","journal-title":"Proc Natl Acad Sci USA"},{"key":"560_CR65","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.1038\/s41598-018-24904-z","volume":"8","author":"JN Rauch","year":"2018","unstructured":"Rauch JN, Chen JJ, Sorum AW, Miller GM, Sharf T, See SK, Hsieh-Wilson LC, Kampmann M, Kosik KS. Tau internalization is regulated by 6-O sulfation on Heparan sulfate proteoglycans. Sci Rep. 2018;8:6382.","journal-title":"Sci Rep"},{"key":"560_CR66","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1523\/JNEUROSCI.5491-10.2011","volume":"31","author":"T Kanekiyo","year":"2011","unstructured":"Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J Neurosci. 2011;31:1644\u201351.","journal-title":"J Neurosci"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-022-00560-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-022-00560-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T06:06:29Z","timestamp":1662098789000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-022-00560-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1186\/s13024-022-00560-w","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"assertion":[{"value":"31 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.B. consults for SciNeuro, has consulted for AbbVie, E-Scape, Eisai, and Vida Ventures and is on the scientific advisory board for Kisbee Therapeutics. D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Genentech, Denali and Cajal Neuroscience and consults for Alector. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}